Skip to main content

brivaracetam (Briviact®)

 

Status: Recommended with restrictions

Brivaracetam (Briviact®) is recommended as an option for restricted use within NHS Wales

Brivaracetam (Briviact®) should be restricted for use in the treatment of patients with refractory epilepsy, who remain uncontrolled with, or are intolerant to, other adjunctive anti-epileptic medicines, within its licensed indication as adjunctive therapy in the treatment of partial-onset seizures (POS) with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.

 Final Recommendation: brivaracetam (Briviact) 4614 (PDF, 424Kb)

Medicine details

Medicine name brivaracetam (Briviact®)
Formulation 10 mg, 25 mg, 50 mg, 75 mg, 100 mg film-coated tablets; 10 mg/ml oral solution; 10 mg/ml solution for injection/infusion
Reference number 4614
Indication

Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy

Company UCB Pharma Ltd
BNF chapter Central nervous system
Submission type Licence extension for paediatric use
Status Recommended with restrictions
Advice number 1322
AWMSG meeting date 12/07/2022
Date of issue 19/07/2022
Further information

This advice incorporates and replaces the AWMSG recommendation for brivaracetam (Briviact®) for restricted use in the treatment of patients with refractory epilepsy, in adults, adolescents and children from 4 years of age (Advice number 2318, originally published December 2018).

 

Follow AWTTC: